3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
17
Active not recruiting
17
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasm Metastasis
2
Lymphoma, Follicular
2
Glioma
2
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hereditary Sensory and Autonomic Neuropathies
1
Glioblastoma
1
Diffuse Intrinsic Pontine Glioma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Interventions
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Has announcements
×
Breast Neoplasms
×
Clear all
NCT03248492
2025-06-26
DESTINY-Breast01
Daiichi Sankyo
Phase 2
Terminated
253 enrolled
21 charts
1 FDA